



**Supplementary Figure 1. Intracellular TNF $\alpha$  expression in monocytes derived from wild type and mutation-carrier patients.** Intracellular TNF $\alpha$  expression in monocytes derived from patients affected by Crohn's disease (CD), grouped into Wild Type (WT), heterozygous (HET) and homozygous (HOM) for the three *NOD2* polymorphisms (R702W, G908R and L1007Pfs\*2). Data are presented as mean  $\pm$  SEM. No statistical significances were found. (R702W: WT 14.9 $\pm$ 2.7, HET 6.4 $\pm$ 4.0, HOM 17.9 $\pm$ 0; G908R: WT 15.2 $\pm$ 2.9, HET 10.1 $\pm$ 2.6; L1007Pfs\*2 14.2 $\pm$ 2.6, HET 15.6 $\pm$ 7.2)

**Supplementary table 1. Clinical characteristics and *NOD2* genotype of IBD patients**

Clinical characteristics						Inflammatory markers			NOD2 genotypes		
PATIENTS	SEX/AGE	DIAGNOSIS	DISEASE ACTIVITY	ACTIVITY INDEX	THERAPIES	CRP	ESR	FECAL CALPROTECTIN	C>T R702W	G>C G908R	InsC L1007Pfs*2
01	M/18	UC	ACTIVE	15	5ASA, CS	0.47	14	769	NA	NA	NA
02	M/7	UC	ACTIVE	20	-	0.82	47	1522	NA	NA	NA
03	F/18	CD	REMISSION	0	-	0.1	7	NA	C/C	G/G	InsC/-
04	M/19	CD	REMISSION	0	AZA	0.8	6	NA	T/T	G/G	-/-
05	M/6	CD	REMISSION	0	-	0.17	15	NA	C/C	G/G	-/-
06	F/13	CD	ACTIVE	10	ADA	0.71	66	NA	C/C	G/G	-/-
07	M/12	CD	REMISSION	0	5ASA	0.14	14	NA	C/T	G/G	InsC/-
08	F/0	UC	ACTIVE	50	CS	0.68	10	1031	NA	NA	NA
09	M/20	CD	REMISSION	0	Thd	0.11	6	61	C/C	G/G	-/-
10	F/17	CD	REMISSION	10	Thd, CS	0.17	20	NA	NA	NA	NA
11	F/5	UC	REMISSION	0	5ASA	0.24	15	32	NA	NA	NA
12	F/14	CD	REMISSION	5	IFX	0.02	15	NA	C/C	G/G	-/-
13	M/15	UC	REMISSION	0	5ASA	0.07	22	NA	NA	NA	NA
14	M/10	CD	ACTIVE	27.5	-	5.01	33	8668	C/C	G/C	-/-
15	F/11	UC	REMISSION	0	5ASA	0.01	9	238	NA	NA	NA
16	M/17	UC	ACTIVE	15	5ASA	0.2	10	NA	NA	NA	NA
17	M/15	CD	REMISSION	0	-	0.06	18	25	C/C	G/G	-/-
18	M/15	CD	ACTIVE	27.5	IFX	1.25	34	1681	C/C	G/C	InsC/-
19	M/19	UC	REMISSION	5	CS, 5ASA	0.04	8	NA	NA	NA	NA
20	F/14	UC	ACTIVE	40	IFX	1.15	31	NA	NA	NA	NA
21	F/14	UC	ACTIVE	20	IFX	0.23	27	NA	NA	NA	NA
22	F/18	UC	REMISSION	0	AZA, 5ASA	0.06	13	6,6	NA	NA	NA
23	M/17	UC	ACTIVE	15	AZA	2.05	67	2061	NA	NA	NA
24	F/19	CD	REMISSION	0	IFX	0.41	11	NA	C/T	G/G	-/-
25	F/11	CD	ACTIVE	40	-	2.96	120	1372	C/C	G/C	-/-
26	M/16	CD	REMISSION	0	AZA	0.01	7	NA	C/C	G/G	-/-

Clinical characteristics						Inflammatory markers			NOD2 genotypes		
PATIENTS	SEX/AGE	DIAGNOSIS	DISEASE ACTIVITY	ACTIVITY INDEX	THERAPIES	CRP	ESR	FECAL CALPROTECTIN	C>T R702W	G>C G908R	InsC L1007Pfs*2
27	M/15	CD	REMISSION	0	Thd, CS	NA	24	NA	NA	NA	NA
28	M/16	CD	ACTIVE	45	CS, 5ASA	4.9	75	NA	C/C	G/G	-/-
29	F/15	UC	ACTIVE	40	CS,AZA, 5ASA	0.04	33	2120	NA	NA	NA
30	M/13	CD	REMISSION	2.5	ADA	0.1	27	NA	C/C	G/G	-/-
31	M/11	UC	REMISSION	0	AZA, 5ASA	0.08	32	633	NA	NA	NA
32	M/12	CD	REMISSION	5	IFX, 5ASA	0.65	54	71	C/C	G/G	-/-
33	M/18	UC	ACTIVE	37.5	CS, 5ASA	1.81	31	NA	NA	NA	NA
34	M/10	UC	REMISSION	0	AZA, 5ASA	0.01	13	35	NA	NA	NA
35	F/13	UC	ACTIVE	NA	-	0.14	50	NA	NA	NA	NA
36	F/14	UC	ACTIVE	5	AZA, 5ASA	0.26	94	33	NA	NA	NA
37	F/13	UC	ACTIVE	45	-	1.49	58	1800	NA	NA	NA
38	M/2	UC	ACTIVE	20	CS,AZA, 5ASA	0.02	15	286	NA	NA	NA
39	M/8	CD	ACTIVE	12.5	Thd	0.06	46	NA	C/C	G/G	-/-
40	F/16	CD	REMISSION	0	Thd	0.39	15	NA	C/C	G/G	-/-
41	M/16	UC	REMISSION	0	Thd, 5ASA	0.61	9	116	NA	NA	NA
42	M/16	CD	ACTIVE	10	CS	1.21	18	1053	C/C	G/G	-/-
43	F/16	UC	ACTIVE	15	Thd, 5ASA	0.31	49	2177	NA	NA	NA
44	F/17	CD	ACTIVE	27.5	IFX	0.21	44	NA	C/C	G/G	InsC/-
45	F/17	CD	REMISSION	2.5	IFX	0.4	35	NA	C/C	G/G	InsC/-
46	M/17	CD	REMISSION	2.5	AZA	0.2	23	NA	C/C	G/G	-/-
47	M/14	CD	REMISSION	5	-	0.09	14	67	C/C	G/C	InsC/-
48	M/9	UC	REMISSION	0	5ASA	0.03	10	48	NA	NA	NA
49	M/11	CD	REMISSION	0	AZA	0.03	8	NA	C/C	G/G	-/-
50	F/4	UC	REMISSION	0	CS, 5ASA	0.05	21	17	NA	NA	NA
51	F/14	UC	ACTIVE	30	5ASA	0.51	27	15800	NA	NA	NA
52	M/20	UC	REMISSION	0	IFX	0.06	6	NA	NA	NA	NA
53	M/16	CD	REMISSION	2.5	AZA	2.1	21	366	C/C	G/G	InsC/-
54	M/11	CD	ACTIVE	25	IFX	1.0	37	1051	C/C	G/C	-/-

Clinical characteristics						Inflammatory markers			NOD2 genotypes		
PATIENTS	SEX/AGE	DIAGNOSIS	DISEASE ACTIVITY	ACTIVITY INDEX	THERAPIES	CRP	ESR	CALPROTECTIN	C>T R702W	G>C G908R	InsC L1007Pfs*2
55	F/8	UC	ACTIVE	0	5ASA	0.3	20	1402	NA	NA	NA
56	F/10	CD	ACTIVE	25	-	2.07	56	1863	C/C	G/G	-/-
57	M/13	UC	ACTIVE	30	-	0.1	24	1660	NA	NA	NA
58	F/19	UC	ACTIVE	10	5ASA	0.2	15	539	NA	NA	NA
59	M/2	CD	ACTIVE	NA	NA	NA	NA	NA	C/C	G/G	-/-
60	M/2	CD	REMISSION	NA	NA	NA	NA	NA	C/C	G/G	-/-
61	F/10	CD	ACTIVE	20	-	3.18	77	1477	C/C	G/G	-/-
62	F/10	CD	ACTIVE	17.5	IFX	0.19	31	NA	C/C	G/G	-/-
63	M/10	CD	ACTIVE	40	5ASA	1.39	91	980	C/C	G/G	InsC/-
64	F/11	UC	REMISSION	0	AZA, 5ASA	NA	24	106	NA	NA	NA
65	F/3	CD	ACTIVE	35	-	0.85	70	919	C/C	G/G	-/-
66	M/14	UC	ACTIVE	20	5ASA	0.02	22	3700	NA	NA	NA
67	M/12	CD	ACTIVE	7.5	-	0.19	41	807	C/C	G/G	-/-
68	M/12	CD	ACTIVE	2.5	IFX	0.07	23	NA	C/C	G/G	-/-
69	M/17	CD	ACTIVE	5	AZA	0.17	6	277	C/C	G/G	-/-

IBD: Inflammatory Bowel Disease; M: Male; F:Female; CD: Crohn's Disease; UC:Ulcerative Colitis; AZA: Azathioprine; ADA:Adalimumab; Thd: Thalidomide; 5ASA: Mesalamine; IFX: Infliximab; CS: Corticosteroids. AGE(year); CRP (mg/dl), ESR (mm/h); Fecal Calprotectin (mg/Kg); NA: Not Available